Comparison of efficacy of 95-gene and 21-gene classifier (Oncotype DX) for prediction of recurrence in ER-positive and node-negative breast cancer patients

Breast Cancer Research and Treatment

Volumn 140, Issue 2, 2013, Pages 299-306

  Naoi, Yasuto ^a   Kishi, Kazuki ^b   Tsunashima, Ryo ^a   Shimazu, Kenzo ^a   Shimomura, Atsushi ^a   Maruyama, Naomi ^a   Shimoda, Masafumi ^a   Kagara, Naofumi ^a   Baba, Yosuke ^b   Kim, Seung Jin ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

Breast cancer; DNA microarray; ER positive; Prognostic prediction

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GOSERELIN; PACLITAXEL; PROGESTERONE RECEPTOR; TAMOXIFEN; TOREMIFENE; ERBB2 PROTEIN, HUMAN;

21 GENE CLASSIFIER; 95 GENE CLASSIFIER; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CLASSIFIER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DNA MICROARRAY; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; VALIDATION STUDY; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CANCER STAGING; GENE EXPRESSION PROFILING; GENETICS; PATHOLOGY; PROCEDURES; PROGNOSIS; TUMOR RECURRENCE;

BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN;

EID: 84881474583     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-013-2640-9     Document Type: Article

References (27)

1. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26:721-728
2. Prat A, Ellis MJ, Perou CM (2011) Practical implications of gene-expression-based assays for breast oncologists. Nat Rev Clin Oncol 9:48-57
3. Prat A, Perou CM (2011) Deconstructing the molecular portraits of breast cancer. Mol Oncol 5:5-23
4. Paik S (2011) Is gene array testing to be considered routine now? Breast 20(3):S87-S91
5. Perou CM, Borresen-Dale AL (2011) Systems biology and genomics of breast cancer. Cold Spring Harb Perspect Biol 3(2):a003293. doi: 10.1101/cshperspect. a003293
6. Kim C, Paik S (2010) Gene-expression-based prognostic assays for breast cancer. Nat Rev Clin Oncol 7:340-347
7. Ross JS, Hatzis C, Symmans WF, et al. (2008) Commercialized multigene predictors of clinical outcome for breast cancer. Oncolog 13:477-493
8. Colombo PE, Milanezi F, Weigelt B, Reis-Filho JS (2011) Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction. Breast Cancer Res 13:212
9. Gokmen-Polar Y, Badve S (2012) Molecular profiling assays in breast cancer: are we ready for prime time? Oncolog (Williston Park) 26:350-357, 361
10. Naoi Y, Kishi K, Tanei T, et al. (2011) Development of 95-gene classifier as a powerful predictor of recurrences in node-negative and ER-positive breast cancer patients. Breast Cancer Res Treat 128:633-641
11. Paik S (2007) Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 12:631-635
12. Harris L, Fritsche H, Mennel R, et al. (2007) American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312
13. NCCN Clinical Practice Guidelines in Oncology, Breast Cancer (Version 1.2011). http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
14. Sparano JA (2006) TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer 7:347-350
15. Paik S, Shak S, Tang G, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826
16. Gyorffy B, Benke Z, Lanczky A, et al. (2012) RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data. Breast Cancer Res Treat 132:1025-1034
17. Tsunashima R, Naoi Y, Kishi K, et al. (2012) Estrogen receptor positive breast cancer identified by 95-gene classifier as at high risk for relapse shows better response to neoadjuvant chemotherapy. Cancer Lett 324:42-47
18. Naoi Y, Kishi K, Tanei T, et al. (2011) Prediction of pathologic complete response to sequential paclitaxel and 5-fluorouracil/epirubicin/ cyclophosphamide therapy using a 70-gene classifier for breast cancers. Cancer 117:3682-3690
19. Naoi Y, Tanei T, Kishi K, et al. (2012) 70-Gene classifier for differentiation between paclitaxel- and docetaxel-sensitive breast cancers. Cancer Lett 314:206-212
20. Parker JS, Mullins M, Cheang MC, et al. (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160-1167
21. Morimoto K, Kim SJ, Tanei T, et al. (2009) Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression. Cancer Sci 100:1062-1068
22. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403-410
23. Goldstein DR (2006) Partition resampling and extrapolation averaging: approximation methods for quantifying gene expression in large numbers of short oligonucleotide arrays. Bioinformatics 22:2364-2372
24. Katz S, Irizarry RA, Lin X, et al. (2006) A summarization approach for Affymetrix GeneChip data using a reference training set from a large, biologically diverse database. BMC Bioinformatics 7:464
25. Irizarry RA, Hobbs B, Collin F, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4:249-264
26. Chang JC, Makris A, Gutierrez MC, et al. (2008) Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients. Breast Cancer Res Treat 108:233-240
27. Symmans WF, Hatzis C, Sotiriou C, et al. (2010) Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 28:4111-4119